Herpes vaccines could mean billions of dollars of cost savings and prevent the loss of millions of quality of life years by reducing HSV-2 infections and HSV-2 driven HIV infections, according to a modelling study in 90 low and middle income countries

Peer-Reviewed Publication

PLOS

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003938

Article Title: Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study

Author Countries: United States, Qatar

Funding: HHA acknowledges the joint support of Qatar University and Marubeni M-QJRC-2020-5. LJA acknowledges the support of NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

---

JOURNAL

PLoS Medicine

DOI

10.1371/journal.pmed.1003938 

METHOD OF RESEARCH

Observational study

SUBJECT OF RESEARCH

People